SCHEMBL15096355

SCHEMBL15096355

COc1ccc(Oc2cncc(Cl)c2)c(C#N)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.53
CYP3A4 P08684 1/20 0.53
SLC22A12 Q96S37 4/20 0.53
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
CYP19A1 P11511 2/20 0.45
CYP11B1 P15538 2/20 0.44
CYP11B2 P19099 2/20 0.44
CLK1 P49759 2/20 0.44
CDK5 Q00535 2/20 0.44
DYRK1A Q13627 2/20 0.44
CDK5R1 Q15078 2/20 0.44
CLK2 P49760 1/20 0.44
CLK3 P49761 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
EPAS1 Q99814 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15096359 0.85 SLC22A12 (0.52) SLC22A12POLBGAACYP19A1CYP11B1
SCHEMBL1871431 0.82 CYP3A4 (0.54) PPARGCYP3A4SLC22A12CYP19A1CYP11B1
SCHEMBL875153 0.80 PPARG (0.52) PPARGCYP3A4SLC22A12CYP19A1CYP11B1
SCHEMBL15832086 0.80 POLB (0.47) SLC22A12POLBGAACYP19A1ALDH1A1
SCHEMBL12642884 0.79 PPARG (0.53) PPARGCYP3A4SLC22A12CYP19A1CYP11B1
SCHEMBL875726 0.79 CYP3A4 (0.51) PPARGCYP3A4SLC22A12CYP19A1CYP11B1
SCHEMBL876329 0.79 PPARG (0.53) PPARGCYP3A4SLC22A12CYP19A1CYP11B1
SCHEMBL875285 0.79 CYP3A4 (0.51) PPARGCYP3A4SLC22A12CYP19A1CYP11B1
SCHEMBL2034653 0.78 SLC22A12 (0.63) PPARGCYP3A4SLC22A12EPAS1
SCHEMBL2031800 0.77 PPARG (0.52) PPARGCYP3A4SLC22A12ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 PPARG 744/4885CYP3A4 2625/4885SLC22A12 2850/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 PPARG 744/4885CYP3A4 2625/4885SLC22A12 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.